logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY

Everybody knows Bristol-Myers Squibb (BMY) , but just a few may know anything about CytomX Therapeutics (CTMX ) , or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads...

Read More

March 23, 2017

0

Why Investors Caused a Selloff of Alnylam’s Stock

Alnylam (ALN)  is probably experiencing a stock selloff following the announcement of successful results from  Pfizer’s (PFE)  drug tafamidis.    Indeed, results from Phase 3 ATT-ACT clinical trial demonstrate that tafamidis succeeded in treating Transthyretin Cardiomyopathy,  a  subtype of TTR amyloidosis...

Read More

April 2, 2018

0

About the Celyad/Horizon discovery agreement

Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc,  for the use of its shRNA technology to generate Celyad’s second non-gene-edited allogeneic platform. The encouragement came from data emanating from preclinical studies demonstrating the versatility of the shRNA...

Read More

November 1, 2018

0

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If  They Sell the Best of the Best  Biotechnology Firms Only Because the Market Is Weird   Even if one is scared and feels he should sell shares, he must be wise...

Read More

April 5, 2018

0

About Exelixis

Exelixis (EXEL) provided an update that testified to its solid fundamentals, the growth of its approved products’ sales, the professionalism and seriousness of its management. Revenues: Exelixis’ total quarter revenues were  $225.4 million vs. $152.5 million  for the comparable period...

Read More

November 2, 2018

0

Agenus Reform and Downsizing. Innoviva's Voting Dilemma

Agenus (AGEN ) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program. Among others are: - Closing its Basel site and...

Read More

March 30, 2017

0

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

NOVARTIS TO ACQUIRE AVEXIS A few months ago,  Novartis (NVS)  CEO agreed to cash out of the company’s consumer health joint venture with   GlaxoSmithKline (GSK) , which brought in cash intended to further improve and expand Novartis’ pipeline. Here...

Read More

April 10, 2018

0

Advancements in Cancer Immunotherapy. See Also: A Small Firm with Promising News

CANCER IMMUNOTHERAPY Nonstop Improvements and Nonstop Discoveries Checkpoint inhibitors and CAR-T immunotherapy are created to stay and succeed and change the way cancer has been treated for decades. The reason is that the successful results from some early attempts to...

Read More

April 8, 2017

0

Illumina’s Contribution to Practicing Precision Medicine

When we reiterated that  Illumina (ILMN)  is the engine of the biotechnology evolution we meant it. We have to add, though, that the evolution made possible by Illumina’s sequencers and next-generation sequencing (NGS) engine is tremendously improving research and medical...

Read More

April 11, 2018

0

The molecule that enhanced the T Cells cancer treatment efficacy while preventing autoimmune diseases

Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we keep reminding ourselves are undervalued. The outperformance unveiled the interred strength of firms such as:  Illumina (ILMN), Amgen (AMGN) and   Vertex (VRTX), t...

Read More

November 8, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 47
  • 48
  • 49
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy